Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)

Lung cancer is the leading cause of cancer death. In France, lung cancer is a common cancer (fourth cause of cancer) with 49,000 new cases diagnosed each year and nearly 29,000 deaths per year.

New therapies (targeted therapies and immune checkpoint inhibitors) are now available and improve patient care. However, their prescription is based on the molecular analysis of the biopsies which are often of very small size, sometimes performed on lesions that are difficult to access, requiring invasive sampling that are difficult to repeat over time.

Identifying biomarkers via different fluids that are easier to access (blood, bronchiolo-alveolar lavage, etc.) therefore is strongly needed to improve screening and diagnosis and to optimize treatment.

The objectives of this biobank are:

To identify diagnostic, theragnostic, prognostic or therapeutic biomarkers in early and advanced stage lung cancer.

To evaluate the prevalence of lung cancer and identify predictive biomarkers for malignancy in patients with lung nodule(s).

To test the feasibility and diagnostic yield of the detection of known biomarkers in non or less invasive biological specimens (blood, urine, other) and analyse the concordance with tissue biopsy.

To identify mechanisms of oncogenesis and identify new molecular targets for anticancer treatment using genomics, transcriptomics or proteomics.

After informed consent, clinical data and biological samples will be collected up to 15 years, at the inclusion of the patients in the cohort, and at each monitoring programmed in their usual care. Up to 10 different biological fluids (blood (up to 55 ml), bronchoalveolar lavage, mediastinal node or mass, or peripheral nodule aspiration supernatant, urine, pleural fluid, cerebrospinal fluid, saliva, nasal swamp, stool) will be obtained depending on the case.

• Identify new biomarkers and/or sets of biomarkers in patients with lung nodules (diagnostic biomarkers) or advanced lung cancer (prognostic or therapeutic biomarkers). [Срок оценки: At the inclusion and up to 15 years after the inclusion]
• Explore whether known tumor markers of interest can be found in other biological samples that are easier to access (urine, blood, etc.). [Срок оценки: At the inclusion and up to 15 years after the inclusion]
• Estimate the concordance of the presence of known and/or newly identified biomarkers of interest in the biological sample(s) of the collection with the tissue biopsy data. [Срок оценки: At the inclusion and up to 15 years after the inclusion]
• Study the evolution over time of the biomarkers of interest and/or newly identified in the biological sample(s) constituting the collection. [Срок оценки: At the inclusion and up to 15 years after the inclusion]
• Explore through molecular and/or genomic and/or transcriptomic and/or proteomic studies the biological mechanisms underlying the development of thoracic cancer to improve screening, diagnosis, therapeutic orientation. [Срок оценки: At the inclusion and up to 15 years after the inclusion]
• Determine the prevalence of bronchial cancer in patients with supracentimetric lung nodules. [Срок оценки: At the inclusion and up to 15 years after the inclusion]